Circulating Cell-free Genome Atlas Study

Mapping the landscape of genomic cancer signals in the blood

The Circulating Cell-free Genome Atlas (CCGA) Study is a prospective, case-control, observational, longitudinal study designed to characterize the methylation patterns on cell-free DNA in the blood of people with and without cancer. The study enrolled approximately 15,000 participants across 142 sites in the United States and Canada, and includes both people who had cancer at the time of enrollment (newly diagnosed, and not yet received treatment) and people who did not have a known cancer diagnosis. Planned follow-up for all participants is at least five years to collect clinical outcome data.

Thank you for your contribution
GRAIL and its collaborators would like to extend a big thank you to all the participants across the United States and Canada who contributed to the CCGA Study. Your participation in the CCGA Study helped GRAIL and its collaborators develop an important new multi-cancer early detection test.

Current Status:
Closed to enrollment

The study enrolled participants who either had a diagnosis of cancer and have not yet received treatment, or are individuals without a current or prior cancer diagnosis. All participants are 20 years of age or older.

View Full Study
avera logo
Cleveland clinic logo
Dana-Farber Log
lahey hospital and medical center logo
Mayo Clinic Logo
MultiCare Yakima Memorial
Ocala Oncology Florida Cancer Affiliates
uhn princess margaret cancer foundation logo
The US Oncology LOGO